Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3',5'-Dibromo-2',4,4',6'-tetrahydroxy aurone** is a synthetic small molecule belonging to the class of aurone flavonoids. Structurally it is an aurone substituted with hydroxy groups at positions 2’, 4, 4’, and 6’ and bromo groups at positions 3’ and 5’. It has been studied as a potent competitor for thyroid hormone binding to human transthyretin (TTR), a serum thyroid hormone transport protein. The compound binds in two distinct modes within the TTR channel and acts as an inhibitor of iodothyronine deiodinase. Its primary research interest lies in its ability to modulate TTR function and potentially disrupt thyroid hormone transport or metabolism[1][6][8]. There are no approved clinical indications or marketed formulations; it remains an experimental compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3',5'-dibromo-2',4,4',6'-tetrahydroxy aurone.